$ATYR
aTyr Pharma Inc

2017 Q1 Form 10-K Financial Statement

#000156459017004631 Filed on March 16, 2017

View on sec.gov

Income Statement

Concept 2017 Q1 2016 Q4 2016
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.010M $3.380M $15.09M
YoY Change -2.67% -11.29% 15.1%
% of Gross Profit
Research & Development $9.204M $9.140M $42.85M
YoY Change -23.3% -27.86% 24.18%
% of Gross Profit
Depreciation & Amortization $226.0K $220.0K $900.0K
YoY Change -3.0% -4.35% 3.57%
% of Gross Profit
Operating Expenses $13.21M $12.53M $57.94M
YoY Change -18.02% -24.0% 21.68%
Operating Profit -$13.21M -$57.94M
YoY Change -18.02% 21.68%
Interest Expense -$60.00K $65.00K
YoY Change 50.0% -116.84%
% of Operating Profit
Other Income/Expense, Net -$194.0K $36.00K
YoY Change -792.86% -110.08%
Pretax Income -$13.41M -$12.62M -$57.90M
YoY Change -16.66% -23.47% 20.7%
Income Tax -$50.00K -$49.00K
% Of Pretax Income
Net Earnings -$13.41M -$12.57M -$57.86M
YoY Change -16.67% -23.81% 20.6%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$7.888M -$7.438M -$34.24M
COMMON SHARES
Basic Shares Outstanding 23.75M 23.72M
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q1 2016 Q4 2016
SHORT-TERM ASSETS
Cash & Short-Term Investments $61.93M $72.15M $72.10M
YoY Change -27.98% -24.48% -24.5%
Cash & Equivalents $28.90M $38.39M $38.40M
Short-Term Investments $33.03M $33.76M $33.80M
Other Short-Term Assets $1.800M $2.600M $2.600M
YoY Change 12.5% 8.33% 8.33%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $63.80M $74.80M $74.80M
YoY Change -27.17% -23.63% -23.67%
LONG-TERM ASSETS
Property, Plant & Equipment $1.600M $1.421M $1.400M
YoY Change -11.11% -20.75% -22.22%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $4.000M $4.000M
YoY Change -86.58% -86.58%
Other Assets $300.0K $333.0K $300.0K
YoY Change 200.0% 182.2% 200.0%
Total Long-Term Assets $1.900M $5.724M $5.700M
YoY Change -93.09% -81.96% -82.02%
TOTAL ASSETS
Total Short-Term Assets $63.80M $74.80M $74.80M
Total Long-Term Assets $1.900M $5.724M $5.700M
Total Assets $65.70M $80.52M $80.50M
YoY Change -42.92% -37.9% -37.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.200M $2.606M $2.600M
YoY Change -79.66% -32.7% -33.33%
Accrued Expenses $4.200M $5.450M $5.500M
YoY Change 16.67% 18.61% 19.57%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $1.094M $339.0K $300.0K
YoY Change -67.82% -89.93% -91.18%
Total Short-Term Liabilities $6.549M $8.525M $8.500M
YoY Change -50.35% -29.82% -29.75%
LONG-TERM LIABILITIES
Long-Term Debt $8.480M $9.198M $9.200M
YoY Change 842.22% 417.91% 411.11%
Other Long-Term Liabilities $0.00 $0.00
YoY Change -100.0% -100.0%
Total Long-Term Liabilities $8.480M $9.198M $9.200M
YoY Change 1422.44% 291.9% 268.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.549M $8.525M $8.500M
Total Long-Term Liabilities $8.480M $9.198M $9.200M
Total Liabilities $15.03M $17.72M $17.70M
YoY Change 9.32% 22.27% 21.23%
SHAREHOLDERS EQUITY
Retained Earnings -$229.4M -$216.0M
YoY Change 31.67% 36.59%
Common Stock $280.2M $278.9M
YoY Change 2.0% 2.02%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $50.71M $62.80M $62.80M
YoY Change
Total Liabilities & Shareholders Equity $65.74M $80.52M $80.50M
YoY Change -42.9% -37.9% -37.93%

Cashflow Statement

Concept 2017 Q1 2016 Q4 2016
OPERATING ACTIVITIES
Net Income -$13.41M -$12.57M -$57.86M
YoY Change -16.67% -23.81% 20.6%
Depreciation, Depletion And Amortization $226.0K $220.0K $900.0K
YoY Change -3.0% -4.35% 3.57%
Cash From Operating Activities -$13.89M -$11.69M -$52.86M
YoY Change 11.21% 18.8% 43.64%
INVESTING ACTIVITIES
Capital Expenditures $262.0K -$50.00K $600.0K
YoY Change -16.56% -54.55% -9.64%
Acquisitions
YoY Change
Other Investing Activities $4.660M $8.650M $34.13M
YoY Change -68.32% 115.17% -147.85%
Cash From Investing Activities $4.400M $8.600M $33.53M
YoY Change -69.42% 119.95% -146.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $1.000K $20.00K
YoY Change -90.91% -96.69%
Debt Paid & Issued, Net $5.202M
YoY Change 60.7%
Cash From Financing Activities 0.000 7.150M 4.697M
YoY Change -100.0% -755.96% -96.82%
NET CHANGE
Cash From Operating Activities -13.89M -11.69M -52.86M
Cash From Investing Activities 4.400M 8.600M 33.53M
Cash From Financing Activities 0.000 7.150M 4.697M
Net Change In Cash -9.490M 4.060M -14.64M
YoY Change -986.92% -157.83% -137.41%
FREE CASH FLOW
Cash From Operating Activities -$13.89M -$11.69M -$52.86M
Capital Expenditures $262.0K -$50.00K $600.0K
Free Cash Flow -$14.15M -$11.64M -$53.46M
YoY Change 10.53% 19.63% 42.7%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15094000
CY2015 us-gaap Operating Expenses
OperatingExpenses
47616000
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
-23554000
CY2016 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2016 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2016 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2016 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2017Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
23748096
CY2016Q2 dei Entity Public Float
EntityPublicFloat
37197028
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
53025000
CY2016Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
33759000
CY2015Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
42510000
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2415000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
97950000
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1793000
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
118000
CY2015Q4 us-gaap Assets
Assets
129675000
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3872000
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4595000
CY2016Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
339000
CY2014 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-796000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
-91010000
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
34504000
CY2014 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16777000
CY2014 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6777000
CY2014 us-gaap Operating Expenses
OperatingExpenses
23554000
CY2016 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
36000
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23670079
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13112000
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
95500000
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23670079
CY2015 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-357000
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23744832
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23744832
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
42846000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2266419
CY2016 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-57760000
CY2016 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
95000
CY2015 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-171000
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.44
CY2014 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-29.69
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23681019
CY2015 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-48144000
CY2014 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24350000
CY2016 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
22902000
CY2015 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
13415000
CY2016Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
4002000
CY2015Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
29814000
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1421000
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
333000
CY2016Q4 us-gaap Assets
Assets
80524000
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2606000
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
71149000
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
33713000
CY2016Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
21624000
CY2016Q4 life Deferred Tax Assets Tax Credit Carryforwards Research And Other State
DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOtherState
9227000
CY2016Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
3874000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
2711000
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5450000
CY2016Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
130000
CY2015Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
315000
CY2015Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
3366000
CY2016Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
9198000
CY2015Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1776000
CY2015Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
571000
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016 us-gaap Operating Expenses
OperatingExpenses
57940000
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-57940000
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
-47616000
CY2016 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
65000
CY2015 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-386000
CY2014 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-832000
CY2016 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-29000
CY2015 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-29000
CY2014 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-36000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-57904000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-47973000
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-24350000
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-49000
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-57855000
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-47973000
CY2015 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
15000
CY2014 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
416000
CY2016 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-57855000
CY2015 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-47988000
CY2014 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-24766000
CY2015 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.03
CY2015 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
15838353
CY2014 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
834221
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
-66082000
CY2014 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
72000
CY2014 life Increase Decrease To Additional Paid In Capital Changes To Share Repurchase Liability
IncreaseDecreaseToAdditionalPaidInCapitalChangesToShareRepurchaseLiability
13000
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1791000
CY2014 life Changes In Equity Dissolution Of Affiliates
ChangesInEquityDissolutionOfAffiliates
-2038000
CY2014 us-gaap Adjustments To Additional Paid In Capital Increase In Carrying Amount Of Redeemable Preferred Stock
AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock
416000
CY2015 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
171284000
CY2015 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
75903000
CY2015 life Adjustments To Additional Paid In Capital And Stockholder Note Receivable
AdjustmentsToAdditionalPaidInCapitalAndStockholderNoteReceivable
60000
CY2015 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
535000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.34
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
11.29
CY2016 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-19687000
CY2015 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-16311000
CY2014 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-8279000
CY2014 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-2023000
CY2014 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
368000
CY2014 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
372000
CY2014 us-gaap Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
144000
CY2014 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-3391000
CY2015 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
1411000
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5029000
CY2015 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4856000
CY2016 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
900000
CY2015 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
869000
CY2014 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
829000
CY2015 life Reclassification Of Convertible Preferred Stock Warrant Liability To Additional Paid In Capital
ReclassificationOfConvertiblePreferredStockWarrantLiabilityToAdditionalPaidInCapital
290000
CY2015 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
1411000
CY2015 life Increase Decrease To Additional Paid In Capital Changes To Share Repurchase Liability
IncreaseDecreaseToAdditionalPaidInCapitalChangesToShareRepurchaseLiability
-120000
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4856000
CY2015 us-gaap Adjustments To Additional Paid In Capital Increase In Carrying Amount Of Redeemable Preferred Stock
AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock
15000
CY2016 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
20000
CY2016 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
143000
CY2016 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
217000
CY2016 life Increase Decrease To Additional Paid In Capital Changes To Share Repurchase Liability
IncreaseDecreaseToAdditionalPaidInCapitalChangesToShareRepurchaseLiability
102000
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5029000
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2668613
CY2016 life Weighted Average Common Shares Outstanding
WeightedAverageCommonSharesOutstanding
23707003
CY2015 life Weighted Average Common Shares Outstanding
WeightedAverageCommonSharesOutstanding
15900167
CY2016 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
28089000
CY2015 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
109445000
CY2014 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
5397000
CY2016 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
62216000
CY2015 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
38115000
CY2014 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
3400000
CY2014 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1791000
CY2016 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
173000
CY2015 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
297000
CY2014 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
426000
CY2016 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-531000
CY2015 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-789000
CY2014 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-43000
CY2016 life Increase Decrease In Deferred Rent Credit
IncreaseDecreaseInDeferredRentCredit
-315000
CY2015 life Increase Decrease In Deferred Rent Credit
IncreaseDecreaseInDeferredRentCredit
-295000
CY2014 life Increase Decrease In Deferred Rent Credit
IncreaseDecreaseInDeferredRentCredit
-277000
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
421000
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
666000
CY2014 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1043000
CY2016 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-932000
CY2015 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3944000
CY2014 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-207000
CY2016 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-52861000
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-36797000
CY2014 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-22824000
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
600000
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
664000
CY2014 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
249000
CY2016 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
33527000
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-71994000
CY2014 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-2246000
CY2015 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
75648000
CY2015 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
76902000
CY2014 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
999000
CY2016 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
20000
CY2015 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
604000
CY2014 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
72000
CY2016 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
143000
CY2016 us-gaap Proceeds From Repayments Of Debt
ProceedsFromRepaymentsOfDebt
9736000
CY2014 us-gaap Proceeds From Repayments Of Debt
ProceedsFromRepaymentsOfDebt
5000000
CY2016 us-gaap Repayments Of Bank Debt
RepaymentsOfBankDebt
5202000
CY2015 us-gaap Repayments Of Bank Debt
RepaymentsOfBankDebt
3237000
CY2014 us-gaap Repayments Of Bank Debt
RepaymentsOfBankDebt
1561000
CY2015 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
2000000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
4697000
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
147917000
CY2014 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
2512000
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-14637000
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
39126000
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-22558000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13899000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36457000
CY2016 us-gaap Interest Paid
InterestPaid
225000
CY2015 us-gaap Interest Paid
InterestPaid
925000
CY2014 us-gaap Interest Paid
InterestPaid
415000
CY2016 life Issuance Of Warrants In Connection With Borrowings
IssuanceOfWarrantsInConnectionWithBorrowings
217000
CY2014 life Issuance Of Warrants In Connection With Borrowings
IssuanceOfWarrantsInConnectionWithBorrowings
148000
CY2016 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
25984
CY2016 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Our consolidated financial statements are prepared in accordance with generally accepted accounting principles (GAAP). The preparation of our consolidated financial statements requires us to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements and accompanying notes. The most significant estimates in our consolidated financial statements relate to the fair value of equity issuances and awards, and clinical trial and research and development expenses. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ materially from these estimates and assumptions.</p></div>
CY2014 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10873764
CY2016Q4 us-gaap Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear
11
CY2016 life Available For Sale Securities In Gross Unrealized Loss Position Maturities Term Maximum
AvailableForSaleSecuritiesInGrossUnrealizedLossPositionMaturitiesTermMaximum
P12M
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6053000
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5541000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4632000
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3748000
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1977000
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1710000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3473000
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2885000
CY2015 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
61814
CY2016 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.17%;">Financial instruments that potentially subject us to significant concentration of credit risk consist primarily of cash, cash equivalents and investment securities. We have established guidelines regarding diversification of investments and their maturities, which are designed to maintain principal and maximize liquidity. We maintain deposits in federally insured financial institutions in excess of federally insured limits. We have not experienced any losses in such accounts and we believe that we are not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</p></div>
CY2015Q4 us-gaap Net Income Loss
NetIncomeLoss
-16493000
CY2015Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.70
CY2016 life Registration Statement Filing Date
RegistrationStatementFilingDate
2016-06-13
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2625280
CY2016 us-gaap Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
0
CY2016Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
37800000
CY2016 life Adjustment Of Amortized Cost And Fair Value Of Investment Securities
AdjustmentOfAmortizedCostAndFairValueOfInvestmentSecurities
27000
CY2016 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2014 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
61457
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4250049
CY2014 life Weighted Average Common Shares Outstanding
WeightedAverageCommonSharesOutstanding
895678
CY2016 us-gaap Debt Instrument Payment Terms
DebtInstrumentPaymentTerms
(i) $10.0 million which was funded on November 18, 2016; (ii) $5.0 million may be drawn down by us at any time before the earlier of June 30, 2017 or an event of default, at our discretion, subject to achievement of certain financial and clinical milestones; and (iii) $5.0 million may be drawn down by us any time after June 30, 2017 and before the earlier of December 31, 2017 or an event of default, at our discretion, subject to achievement of certain milestones specified for the second tranche and additional financial and clinical milestones.
CY2016 life Noncancelable Operating Leases Term Of Expiration
NoncancelableOperatingLeasesTermOfExpiration
2017-05
CY2011Q4 life Lease Agreement Option To Extend Lease Term
LeaseAgreementOptionToExtendLeaseTerm
P5Y
CY2016 life Noncancelable Operating Leases Term Of Extension
NoncancelableOperatingLeasesTermOfExtension
2019-05
CY2016 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
500000
CY2015 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
400000
CY2014 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
200000
CY2015Q2 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
2000000
CY2015Q2 us-gaap Interest Paid
InterestPaid
500000
CY2016Q2 life Sublease Agreement Commenced Date
SubleaseAgreementCommencedDate
2016-08
CY2016Q2 life Sublease Agreement Expiration Date
SubleaseAgreementExpirationDate
2017-06
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
386000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
386000
CY2016 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
15892
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
860819
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4014988
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4014988
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1419562
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.83
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.56
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.24
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
10.17
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.73
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
6.73
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.27
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M26D
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y9M26D
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y10M17D
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
519000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
519000
CY2016Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
519000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
10.18
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
34000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1900000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
400000
CY2016Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
9600000
CY2016 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y10M24D
CY2016Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
121512
CY2015Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
3782223
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-57096000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-808000
CY2016 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
675000
CY2015 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
865000
CY2016 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
6800000
CY2015 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
2674000
CY2016 us-gaap Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
2720000
CY2015 us-gaap Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
1070000
CY2016 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
141000
CY2015 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
84000
CY2015 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
3551000
CY2014 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
13553000
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
48319000
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
24869000
CY2015Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
14181000
CY2015Q4 life Deferred Tax Assets Tax Credit Carryforwards Research And Other State
DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOtherState
3565000
CY2015Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
4176000
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
1528000
CY2016 life Period Of Change In Ownership
PeriodOfChangeInOwnership
P3Y
CY2016 life Percentage Of Change In Ownership
PercentageOfChangeInOwnership
0.50
CY2016Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2015Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2014Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2015Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
5033000
CY2014Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1106000
CY2013Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
947000
CY2016 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
1890000
CY2015 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
2404000
CY2016 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
6077000
CY2015 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
1523000
CY2014 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
177000
CY2014 life Unrecognized Tax Benefits Period Increase Decrease Other
UnrecognizedTaxBenefitsPeriodIncreaseDecreaseOther
-18000
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
13000000
CY2016Q4 us-gaap Increase In Unrecognized Tax Benefits Is Reasonably Possible
IncreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
0
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
16115000
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
15433000
CY2016Q3 us-gaap Operating Expenses
OperatingExpenses
13865000
CY2016Q4 us-gaap Operating Expenses
OperatingExpenses
12527000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-16087000
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-15383000
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-13819000
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
-12566000
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.68
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.65
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.58
CY2016Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.53
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
8922000
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
10898000
CY2015Q3 us-gaap Operating Expenses
OperatingExpenses
11313000
CY2015Q4 us-gaap Operating Expenses
OperatingExpenses
16483000
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-9071000
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-11080000
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-11329000
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-9.39
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.74
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.48

Files In Submission

Name View Source Status
0001564590-17-004631-index-headers.html Edgar Link pending
0001564590-17-004631-index.html Edgar Link pending
0001564590-17-004631.txt Edgar Link pending
0001564590-17-004631-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g2017031619390936938780.jpg Edgar Link pending
g2017031619391050844702.jpg Edgar Link pending
g2017031619391441640074.jpg Edgar Link pending
g2017031619391441740074.jpg Edgar Link pending
g2017031619391441840074.jpg Edgar Link pending
g2017031619392788640830.jpg Edgar Link pending
g2017031619392791340831.jpg Edgar Link pending
g2017031619392810440832.jpg Edgar Link pending
g2017031619392813440833.jpg Edgar Link pending
g2017031619392814640834.jpg Edgar Link pending
g2017031619394119740835.jpg Edgar Link pending
life-10k_20161231.htm Edgar Link pending
life-20161231.xml Edgar Link completed
life-20161231.xsd Edgar Link pending
life-20161231_cal.xml Edgar Link unprocessable
life-20161231_def.xml Edgar Link unprocessable
life-20161231_lab.xml Edgar Link unprocessable
life-20161231_pre.xml Edgar Link unprocessable
life-ex1017_1754.htm Edgar Link pending
life-ex1018_1377.htm Edgar Link pending
life-ex1019_1376.htm Edgar Link pending
life-ex108_1378.htm Edgar Link pending
life-ex231_1380.htm Edgar Link pending
life-ex311_14.htm Edgar Link pending
life-ex312_12.htm Edgar Link pending
life-ex321_11.htm Edgar Link pending
life-ex322_6.htm Edgar Link pending
life-ex45_669.htm Edgar Link pending
life-ex46_668.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending